To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Drug Therapy Shows Promise In Preventing Hepatitis Infection In Transplant Recipients URL: http://www.pslgroup.com/dg/BEF56.htm Doctor's Guide November 6, 1998
PITTSBURGH, PA -- November 6, 1998 -- Livers from hepatitis B positive donors were safely transplanted and a combination drug treatment prevented infection in recipients of those livers, a University of Pittsburgh Medical Center (UPMC) researcher.
These results will be reported at the 49th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Chicago Nov. 6-10 by S. Forrest Dodson, M.D., assistant professor of surgery at the Starzl Transplantation Institute.
The results of the preliminary study are among more than 30 presentations by UPMC researchers, including three singled out by the AASLD for their scientific merits and study design.
In the face of a chronic shortage of organ donors, surgeons must often consider transplanting organs that may be considered less optimal or high risk. For example, if the only option available to save a patient's life is to transplant a liver from a donor who tests positive for hepatitis B (anti-HBc positive), a surgeon may do so even if it places the recipient at an increased risk for becoming infected with the virus. Post-transplant hepatitis B infection, which is usually evident within six months, is difficult to treat and can eventually lead to cirrhosis of the transplanted liver, thus requiring a second transplant.
But according to the UPMC study, a combination therapy of hepatitis B immune globulin (HBIG) and lamivudine has the potential to stave off post-transplant infection in patients not immune to hepatitis B who receive hepatitis B positive livers.
Twelve patients who received the combination therapy -- which started during the transplant operation and continued for 18 months -- continue to be free of infection between five and 25 months post-transplant, according to the study's lead author, Andrew Bonham, M.D., assistant professor of surgery at the Thomas E. Starzl Transplantation Institute.
Four of these patients, who were ICU-bound before their transplants, had never been exposed to hepatitis (anti-HBs negative) and had no immunity to the virus (anti-HBc negative). Eight others, most of whom were also listed in the most urgent status categories, had previously been exposed to the virus but had not developed immunity. One patient received only HBIG therapy because in 1996, at the time of his transplant, lamivudine was not available for these patients. The patient, who had not been exposed and had no immunity, became infected with the virus six months after transplantation. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.